Patent number

Description

Assignee

Inventor

Date

US 10,413,588

Methods providing a pre/probiotic agent to a subject. Human Intelectin 1 (hIntL-1) has been shown to bind selectively to glycan components on bacteria, thereby promoting and protecting the microbiome.

Wisconsin Alumni Research Foundation (Madison, WI, USA)

Kiessling LL, Wesener DA, Rey F, Wangkanont K

9/17/2019

US 10,410,749

A method for at least one of characterizing, diagnosing and treating a cutaneous condition in at least a subject, the method comprising: receiving an aggregate set of biological samples from a population of subjects; generating at least one of a microbiome composition dataset and a microbiome functional diversity dataset for the population of subjects; generating a characterization of the cutaneous condition based upon features extracted from at least one of the microbiome composition dataset and the microbiome functional diversity dataset; on the basis of the characterization, generating a therapy model configured to correct the cutaneous condition; and at an output device associated with the subject, promoting a therapy to the subject based upon the characterization and the therapy model.

uBiome (San Francisco)

Apte Z, Almonacid D, Richman J, Behbahani SR

9/10/2019

US 10,398,154

Isolated microorganisms—including novel strains of the microorganisms—microbial consortia, and compositions comprising the same. Furthermore, methods of utilizing the described microorganisms, microbial consortia, and compositions comprising the same, in methods for modulating the production and yield of milk and milk components in ruminants.

Ascus Biosciences, (San Diego)

Embree M, Picking L, Gogul G, Tarasova J

9/3/2019

US 10,369,111

The development of a targeted delivery system for the oral delivery of probiotics or therapeutic agent for various indications, including and not limited to active and prophylactic treatment of Clostridium difficile infection, antibiotic-associated diarrhea, irritable bowel syndrome, Crohn’s disease, intestinal flora replacement, supplemental flora treatments for patients taking antibiotics, and for restoration of balance and signaling between the intestinal microbiome and the intestinal cells in patients under treatment of metabolic syndrome manifestations; specifically, diabetes, insulin resistance, obesity, hyperlipidemia and hypertension.

Therabiome (Marlboro, NJ, USA)

Kabadi M, Schentag JJ

8/6/2019

US 10,314,866

Compositions, systems and methods of improving the health of the microbiome of an individual’s skin, relating to the provision of skin-contacting formulations containing beneficial bacteria and other microbe components to foster the growth and maintenance of a healthy skin microbiome.

Kovarik JE

Kovarik JE

6/11/2019

US 10,253,377

Systems and methods to assess the health of various microbiomes and to identity species therein. Described assessments and identifications can inform treatment decisions if a microbiome is determined to have a less than optimal balance of bacterial species within it, the presence of one or more negative species, and/or the absence of one or more positive species.

Wayne State University (Detroit, MI, USA)

Akins RA, Sobel JD

4/19/2019

US 10,206,958

Compositions that have substantially purified Christensenellaceae bacteria, and uses of these compositions to alter the microbiome of an individual. The addition of Christensenellaceae bacteria, such as Christensenella, to the microbiome of an individual can treat or prevent weight gain, reduce body weight, inhibit fat accumulation, reduce excess adiposity and reduce a high body mass index, and can also treat or prevent conditions correlating with excess weight and fat and a high body mass index, such as insulin sensitivity, metabolic syndrome, excess adiposity and diabetes.

Cornell University (Ithaca, NY, USA)

Ley RE, Goodrich J, Waters J

2/19/2019

  1. Source: United States Patent and Trademark Office (http://www.uspto.gov).